REVIEW Nilvadipine is a racemic dihydropyridine calcium channel blocker for the treatment of hypertension and chronic major cerebral artery occlusion. It inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Sato, Yoshinari 2-Methyldihydropyridine derivatives and pharmaceutical composition containing it Ger. Offen. (1980), DE 2940833 A1 19800430.
Satu, Yoshinari 1,4-Dihydropyridine derivatives, and their pharmaceutical use U.S. (1981), US 4284634 A 19810818.
Satoh, Yoshinari; Ichihashi, Masaharu; Okumura, Kazuo Studies on nilvadipine. I. Synthesis and structure-activity relationships of 1,4-dihydropyridines containing novel substituents at the 2-position Chemical & Pharmaceutical Bulletin (1991), 39(12), 3189-201.
Honerjäger P, Seibel K, Pharmacodynamics of nilvadipine, a new dihydropyridine-type calcium antagonist. J Cardiovasc Pharmacol. 1992;20 Suppl 6:S15-21.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.